Positive News SentimentPositive News CorMedix Stock Price, News & Analysis (NASDAQ:CRMD) $3.56 -0.01 (-0.28%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$3.51▼$3.7450-Day Range$3.00▼$4.0152-Week Range$2.57▼$6.09Volume933,766 shsAverage Volume568,008 shsMarket Capitalization$195.13 millionP/E RatioN/ADividend YieldN/APrice Target$14.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media CorMedix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside300.3% Upside$14.25 Price TargetShort InterestBearish12.15% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.80) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector639th out of 954 stocksPharmaceutical Preparations Industry235th out of 362 stocks 3.5 Analyst's Opinion Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.25, CorMedix has a forecasted upside of 300.3% from its current price of $3.56.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.15% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in CorMedix has recently increased by 17.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRMD. Previous Next 3.1 News and Social Media Coverage News SentimentCorMedix has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CorMedix this week, compared to 1 article on an average week.Search Interest14 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of CorMedix is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CorMedix are expected to decrease in the coming year, from ($0.80) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CorMedix Stock (NASDAQ:CRMD)CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More CRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRMD Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comCorMedix Inc. Announces Partnership With The Leapfrog GroupNovember 27, 2023 | msn.comCorMedix (CRMD) Price Target Increased by 15.54% to 14.54December 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | msn.comWhy CorMedix Stock Popped WednesdayNovember 15, 2023 | finance.yahoo.comCorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis PatientsNovember 15, 2023 | marketwatch.comCorMedix Shares Surge 17% on Better-Than-Expected Loss per ShareNovember 15, 2023 | msn.comCorMedix rallies on FDA nod for anti-infective agent DefenCathNovember 15, 2023 | reuters.comU.S. FDA approves CorMedix's antimicrobial drugDecember 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cormedix (CRMD), Immatics (IMTX) and Johnson & Johnson (JNJ)November 15, 2023 | benzinga.comWhy CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving PremarketNovember 15, 2023 | finance.yahoo.comCorMedix Inc. (NASDAQ:CRMD) Q3 2023 Earnings Call TranscriptNovember 15, 2023 | finanznachrichten.deCorMedix, Inc.: CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business UpdateNovember 14, 2023 | seekingalpha.comARCT, MNTS and SNBR are among after hour moversNovember 14, 2023 | fool.comCorMedix (CRMD) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comCormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023November 14, 2023 | msn.comCorMedix GAAP EPS of -$0.17 beats by $0.04November 14, 2023 | finance.yahoo.comCorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | msn.comCorMedix Q3 2023 Earnings PreviewNovember 13, 2023 | markets.businessinsider.comHere's what Wall Street expects from Cormedix's earningsNovember 8, 2023 | morningstar.comCormedix Inc CRMDNovember 2, 2023 | finance.yahoo.comCorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023October 11, 2023 | finance.yahoo.comCorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek ConferenceOctober 5, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Cormedix (CRMD)September 26, 2023 | finance.yahoo.comCorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare ConferenceSeptember 8, 2023 | finance.yahoo.comCorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of NephrologyAugust 30, 2023 | finance.yahoo.comCorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product DefencathSee More Headlines Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$14.25 High Stock Price Target$19.00 Low Stock Price Target$10.00 Potential Upside/Downside+300.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,700,000.00 Net MarginsN/A Pretax Margin-132,646.69% Return on Equity-65.98% Return on Assets-59.01% Debt Debt-to-Equity RatioN/A Current Ratio11.61 Quick Ratio11.61 Sales & Book Value Annual Sales$29,702.00 Price / Sales6,569.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book2.68Miscellaneous Outstanding Shares54,812,000Free Float52,291,000Market Cap$195.13 million OptionableOptionable Beta1.86 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Joseph Todisco MBA (Age 47)CEO & Director Comp: $927.62kDr. Matthew T. David M.D. (Age 45)Executive VP & CFO Comp: $830.64kDr. Phoebe Mounts Esq. (Age 72)Ph.D., EVP, General Counsel, Head of Regulatory, Compliance & Legal and Secretary Comp: $582.22kMs. Elizabeth Masson-Hurlburt B.A. (Age 44)Executive VP and Head of Clinical & Medical Affairs Comp: $538.91kDonna UcciSenior VP & Head of Global QualityDr. Tushar MukherjeeSenior VP & Head of Technical OperationsMs. Erin Mistry (Age 41)Executive VP & Chief Commercial Officer More ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTFoghorn TherapeuticsNASDAQ:FHTXEnanta PharmaceuticalsNASDAQ:ENTASilverback TherapeuticsNASDAQ:SBTXscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 4,401 shares on 11/24/2023Ownership: 0.052%Wolverine Trading LLCSold 11,300 shares on 11/16/2023Ownership: 0.000%AQR Capital Management LLCBought 15,585 shares on 11/15/2023Ownership: 0.028%Ameriprise Financial Inc.Bought 10,700 shares on 11/15/2023Ownership: 0.020%California State Teachers Retirement SystemSold 3,338 shares on 11/14/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions CRMD Stock Analysis - Frequently Asked Questions Should I buy or sell CorMedix stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRMD shares. View CRMD analyst ratings or view top-rated stocks. What is CorMedix's stock price target for 2024? 4 brokerages have issued twelve-month price objectives for CorMedix's stock. Their CRMD share price targets range from $10.00 to $19.00. On average, they anticipate the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 300.3% from the stock's current price. View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts. How have CRMD shares performed in 2023? CorMedix's stock was trading at $4.22 at the start of the year. Since then, CRMD shares have decreased by 15.6% and is now trading at $3.56. View the best growth stocks for 2023 here. When is CorMedix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our CRMD earnings forecast. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. What ETF holds CorMedix's stock ? ETFMG Treatments Testing and Advancements ETF holds 12,811 shares of CRMD stock, representing 0.39% of its portfolio. When did CorMedix's stock split? CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL). Who are CorMedix's major shareholders? CorMedix's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.82%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.26%), Invesco Ltd. (0.10%), Rhumbline Advisers (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CRMD) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.